$50M cell and viral vector manufacturing operation backed by Harvard

Harvard University School of Engineering and Applied Sciences
Harvard and several CDMOs are working together to build a cell and viral vector clinical supply facility in the the Boston area. (The Harvard Crimson)

CDMOs are building cell and viral vector manufacturing facilities left and right, but Harvard says it just isn’t enough, at least to serve the Boston biotech hub. That is why a host of public and private players is working on a $50 million clinical supply manufacturing facility. 

The facility will help researchers at biotechs, universities and hospitals avoid production bottlenecks that can delay clinical material for more than a year, Harvard said in announcing the project today. 

“Currently, major obstacles to getting new treatments into the clinic revolve around production, specifically the pressure placed on highly skilled contract manufacturers to deliver to labs around the region customized, high-quality cells and viral vectors that meet regulatory standards. Because of the backlog, scientists may need to wait as long as 18 months for the essential products they need to carry out their research,” Harvard said. 

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

RELATED: Catalent pulls off $1.2B deal for gene therapy CDMO Paragon Bioservices

The not-for-profit facility, to be built in the Greater Boston area, will have eight clean rooms and offer “preferred access … at favorable pricing” the group says. 

Board members will come from Fujifilm Diosynth Biotechnologies, GE Healthcare Life Sciences and Alexandria Real Estate Equities as well as Harvard and the Massachusetts Institute of Technology. Contributing members include the state, a list of hospitals and MilliporeSigma. 

In addition to manufacturing, the group says the facility will provide training and collaboration with top researchers. 

RELATED: Novartis' Zolgensma faces EU, Japan delays after regulators raise 'manufacturing questions'

This project comes even as drugmakers are getting gene therapies approved and contractors are moving fast to buy or boost capacity to serve the growing viral vector and gene therapy fields. Earlier this year, Catalent dropped $1.2 billion to grab viral vector and gene therapy manufacturer Paragon Bioservices, and Thermo Fisher shelled out $1.7 billion to get viral vector producer Brammer Bio. Thermo Fisher now has a facility in Massachusetts, along with others, while Catalent got one in Baltimore. Other contractors are adding or expanding facilities in the U.S., Europe and Asia.

Suggested Articles

Johnson & Johnson has expanded its COVID-19 vaccine production pact with CDMO Catalent to include work at the manufacturer's Anagni, Italy site.

German vaccine maker CureVac scored an $85 million EU loan to expand manufacturing for its mRNA-based COVID-19 vaccine hopeful.

Learn how drug substance and drug product early development strategies are important for optimization and long-term success.